William P Esler

6PUBLICATIONS

29CO-AUTHORS

Metabolic medicineProcess control and simulationPharmacogenomicsMolecular medicineHaematological tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Oct 07, 2026

Metabolic benefits of ketohexokinase inhibition in individuals with MASLD: a randomized placebo-controlled crossover trial.

|Feb 16, 2024

Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants.

Aarti Sawant-Basak, Arthur J Bergman, Jessica Mancuso

|Dec 14, 2022

A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes.

Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi

|Oct 12, 2021

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.

Roberto A Calle, Neeta B Amin, Santos Carvajal-Gonzalez

|Sep 15, 2020

De novo lipogenesis is essential for platelet production in humans.

Kenneth L Kelly, William J Reagan, Gabriele E Sonnenberg

|May 17, 2019

Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition.

William P Esler, Gregory J Tesz, Marc K Hellerstein

Pageof 1

Frequent Collaborators

Aditi R Saxena

Albert M Kim

Roberto A Calle

Martijn C G J Brouwers

1 joint publications

Raja Sivamani

1 joint publications

Santos Carvajal-Gonzalez

Frank J Geoly

Julie J Purkal

Mark Fitch

Suzana S Bosanac

Frequent Collaborators

Aditi R Saxena

Albert M Kim

Roberto A Calle

Martijn C G J Brouwers